Patient‐reported cognitive impairments and objective neuropsychological deficits in young sarcoma patients undergoing chemotherapy and its comparison to healthy controls: A tertiary health care study from India

Abstract

AbstractThe study aims to investigate the patient‐reported cognitive deficits and objective neuropsychological functions in younger adult (YA) sarcoma patients (16–40 years of age). Ninety patients and 30 age‐matched healthy controls from a single tertiary healthcare hospital, were recruited into four groups: Pre‐chemotherapy (Pre Cx), During chemotherapy (During Cx), Post‐chemotherapy (Post Cx) and Controls. Neurocognitive functions were assessed subjectively using FACT‐Cog v3 questionnaire; objectively using ACE‐III and neuropsychological tests (NPT). FACT‐Cog scores of During Cx (P = .041) and Post Cx (P = .008) groups were significantly lower than Pre Cx group. ACE‐III scores of During Cx (P = .048) and Post Cx (P = .043) groups were lower as compared to Pre Cx group. In addition, reaction times and accuracies of the NPT (Flanker's, Sternberg's and Emotional Stroop tests) were worse (P < .05) in During Cx and Post Cx groups as compared to either Pre Cx or control groups. In the Post Cx group, the dose of chemotherapy showed significant negative correlation with the Sternberg reaction time (P = .040) as well as the scores of language (P = .047), and attention (P = .044) domains of ACE‐III. Observations demonstrate that cancer/chemotherapy‐related neurocognitive deficits fail to improve even after cessation of treatment, and high dosage of chemotherapy used, could be an underlying factor. This emphasizes the need for developing ‘model of care’ in these patients for monitoring the side effects, and possible titration in the therapeutic regimen for sarcoma in YA.